Stock CYTO ALTAMIRA THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Altamira Therapeutics Ltd.

Equities

CYTO

BMG0360L1349

End-of-day quote Nasdaq
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
1.45 USD -3.33% Intraday chart for Altamira Therapeutics Ltd. -11.59% -58.33%
05-01 Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation CI
04-24 Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
AQ
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
AQ
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K
PU
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
AQ
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
AQ
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
AQ
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
AQ
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
AQ
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
Altamira Therapeutics : Corporate Presentation Winter 2023
PU
Altamira Therapeutics : Reverse Share Split - Form 6-K
PU
Altamira Therapeutics Provides Investor and Business Update
AQ
Altamira Therapeutics : Warrant Inducement Agreement - Form 6-K
PU
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
AQ
Altamira Therapeutics : Compliance with Continued Listing Rule - Form 6-K
PU
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
AQ
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
AQ
Altamira Therapeutics : Notice of the Special General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on October 31, 2023 - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTO Stock
  4. News Altamira Therapeutics Ltd.
  5. Press Releases